6 completed, 1 terminated, 1 withdrawn. 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Vaso-occlusive Crisis: new trials by email Literature Review of Vaso-occlusive Crisis trials Research Report on Vaso-occlusive Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Omega 3, Vit D, Zinc sulfate - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis Ketamine - Sickle Cell Disease, Vaso-Occlusive Crisis | Phase 2 | Completed | UCSF Benioff Children's Hospital Oakland | 62 | 2016-06-01 | 2021-04-20 |
| Nitrous Oxide Analgesia Vaso-occlusive Crisis Nitrous oxide 50% - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Completed | Columbia University | 5 | 2013-11-12 | 2026-01-28 |
| A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. Varespladib, Placebo (Normal Saline) - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Terminated | Anthera Pharmaceuticals | 2 | 2012-02-01 | 2014-03-04 |
| Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo Placebo, Dalteparin - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Completed | Duke University | 34 | 2011-05-01 | 2015-02-16 |
| Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis GMI-1070, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Completed | GlycoMimetics Incorporated | 81 | 2010-05-01 | 2020-05-13 |
| Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC) Patient controlled analgesia, nurse-administered intermittent IV bolus opioid therapy (NAIBOD) - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Withdrawn | Johns Hopkins University | 2007-09-01 | 2017-03-24 | |
| IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome A-001, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Completed | Anthera Pharmaceuticals | 30 | 2006-12-01 | 2014-03-04 |
Anemia, Sickle Cell (8) · Vaso-Occlusive Crises (8) · Acute Chest Syndrome (1) · Emergencies (1)
Anemia (8) · Anemia, Hemolytic (8) · Anemia, Hemolytic, Congenital (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemoglobinopathies (8) · Disease Attributes (1) · Lung Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiration Disorders (1) · Respiratory Tract Diseases (1)
Analgesia, Patient-Controlled (1) · Cardiovascular Agents (1) · Dalteparin (1) · Docosahexaenoic Acids (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Hydroxyurea (1) · Ketamine (1) · Morphine (1) · Saline Solution (1) · Simvastatin (1) · Zinc Sulfate (1) · rivipansel (1) · varespladib (1)
Anthera Pharmaceuticals (2) · Beni-Suef University (1) · Columbia University (1) · Duke University (1) · GlycoMimetics Incorporated (1) · Johns Hopkins University (1) · UCSF Benioff Children's Hospital Oakland (1)
United States (7) · Canada (1) · Egypt (1) · Saudi Arabia (1)
Ahmed F Mahmoud Hussein, MS.c (1) · Daniel S Tsze, MD, MPH (1) · Helen Thackray, MD (1) · Jonathan B Cooper-Sood, MD (1) · Marilyn J Telen, MD (1) · Nirmish Shah, MD (1) · Sophie Lanzkron, MD (1)